Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening blood disease that impacts one to two people per million globally. Characterized by the destruction of red blood cells, PNH in its severe form can lead to blood clots, organ damage, and premature death.

While the treatment framework has revolved primarily around managing complications and improving quality of life, recent developments have opened new avenues for the management of PNH, with the potential to vastly augment patient outcomes.

One of the groundbreaking treatments approved by the FDA in recent years is Eculizumab. A monoclonal antibody, it works by blocking the complement system—an element of our immune system—which is involved in the destruction of red blood cells in PNH. Eculizumab has been proven to reduce hemolysis, minimize symptoms, and lower the risk of blood clots, thereby substantially enhancing a patient's life quality. Its successor, Ravulizumab, offers similar benefits but through less frequent dosing, an improvement that adds convenience to effectiveness.

Aiming at similar complementary pathways but with an oral administration route, Pegcetacoplan is another FDA-approved therapy complementing existing treatment options. It binds to an important component of the complement system and stops the catastrophic breakdown of red blood cells. Clinical trials have demonstrated its effectiveness, even as first-line therapy, showcasing the ability to stabilize hemoglobin levels and reduce the need for blood transfusions.

Despite these advancements in PNH treatment, current therapies are not curative. Bone marrow transplantation, the only curative option, is associated with significant risk and is generally considered for individuals unresponsive to eculizumab therapy or with concurrent bone marrow failure syndromes.

One novel treatment trajectory gaining momentum is gene therapy. Given PNH's genetic nature, gene therapy poses the tantalizing possibility of a one-time curative treatment. Preliminary results have shown promise with a strong safety profile and the notable absence of disease activity.

Chimeric antigen receptor (CAR) T-cell therapy has also emerged as a potential option. This cutting-edge therapy genetically modifies a patient’s T cells to express a receptor that targets and eliminates the cells instigating hemolysis.

It's important to note that while these treatments harbor enormous promise, they are in the experimental phase. Rigorous clinical trials are necessary to establish safety, effectiveness, and long-term implications.

In conclusion, recent strides in PNH treatment are making a significant difference in patients' lives, offering regimental diversity and higher efficacy. The horizon for PNH patients is brightening, with promise for better symptom management, minimal side-effects, and the potential for eventual curative solutions. However, the scientific and medical community's ongoing commitment is vital in pushing these emerging treatments from bench to bedside.